Trials / Completed
CompletedNCT06814106
A Single- and Multiple-Dose Study of Enlicitide Chloride (MK-0616) in Healthy Chinese Adult Participants (MK 0616-010)
A Single- and Multiple-Dose Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK-0616 in Healthy Chinese Adult Participants.
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 37 (actual)
- Sponsor
- Merck Sharp & Dohme LLC · Industry
- Sex
- Male
- Age
- 18 Years – 50 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to learn about the safety of enlicitide chloride and how well people tolerate it. Researchers also want to learn what happens to different amounts of enlicitide chloride in a healthy person's body over time.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Enlicitide Chloride | Oral Capsule |
| DRUG | Placebo | Placebo oral capsule matching enlicitide chloride |
Timeline
- Start date
- 2023-03-06
- Primary completion
- 2023-05-08
- Completion
- 2023-05-08
- First posted
- 2025-02-07
- Last updated
- 2025-02-07
Locations
1 site across 1 country: China
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06814106. Inclusion in this directory is not an endorsement.